THE ADELAIDE BIOMANUFACTURING ALLIANCE - adelaide.edu.au - BioCina
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
THE ADELAIDE BIOMANUFACTURING ALLIANCE adelaide.edu.au
HARNESSING
A NEW ERA IN
MEDICINE mRNA vaccine technology is poised to deliver
solutions for highly prevalent infections, diseases
and cancers that are currently intractable.
More powerful and adaptable than
other vaccine platforms, mRNA
approaches promise to enable adequately
resourced and experienced groups to
COVID WILL NOT DISAPPEAR.
efficiently test multiple novel NEW VACCINE FORMULATIONS WILL
formulations in rapid succession.
The University of Pennsylvania’s Professor
BE DEVELOPED TO ACCOUNT FOR
Drew Weissman, who invented the mRNA VARIATIONS IN THE SARS-COV-2
technology licensed to BioNTech/Pfizer
and Moderna for the production of their VIRUS. AS LONG AS THE VIRUS
COVID-19 vaccines, has said he and his KEEPS SPREADING AND MUTATING,
team are currently working on around 30
different mRNA vaccines. These include for WE’LL NEED BOOSTER SHOTS
conditions such as influenza, HIV, hepatitis
C, malaria, tuberculosis and many more. TO KEEP SERIOUS ILLNESS,
Clearly, harnessing this technology and HOSPITALISATION AND
expertise can bring Australia enormous
health and flow-on economic benefits. DEATH RATES DOWN.
The Adelaide Biomanufacturing Professor Matthew Fenton
Alliance (ABA), led by the University National Institute of Allergy and
of Adelaide, stands ready to Infectious Diseases (US)
play its part.
1 The Adelaide Biomanufacturing Alliance
FOUR KEY MISSIONS
Continuous biomanufacturing agents such as mRNA to be wrapped in nanoparticle therapies are at the cutting
in a digital world protective agents such as the lipids that make edge of oncology advances, and will be a
vaccines stable2. World-leading scientists cornerstone for the success of the new
Biomanufacturing has traditionally been and engineers from ABA will improve this $80m SAiGENCI cancer Institute located
done batch by batch. However, a move technology and further enhance the efficacy, in Adelaide. Biomanufacturing capability
toward continuous processing, as done stability and safety of new vaccines and and tools developed by the ABA and
for chemical manufacture, can deliver other therapeutic formulations. SAiGENCI will position Australia at
better quality, more quickly and at lower the forefront of this emerging field.
cost. Continuous processing will move Plasmid process scale-up
biomanufacturing into the 21st Century1.
New challenges will emerge, and digitisation DNA plasmids made in bacterial
- in particular AI - will ensure process fermentation are a key reagent for
robustness and identify process failure in mRNA manufacture. However, large-
real time, thus speeding the journey from scale industrial manufacture is challenging
lab to bedside. This mission leverages new as plasmids are highly sensitive3. In this
research and knowledge from the academics mission, scientists from ABA will create a
within the Adelaide Biomanufacturing series of digital and practical tools to predict 1. Gerstweiler, L, Bi, J and Middelberg, APJ 2021, Continuous
downstream bioprocessing for intensified manufacture of
Alliance (ABA) with the power of machine- flow behaviour of process liquids to speed biopharmaceuticals and antibodies, Chemical Engineering
learning experts in the Australian Institute up production of plasmids and other large Science, vol. 231, 116272, ISSN 0009-2509,
https://doi.org/10.1016/j.ces.2020.116272.
for Machine Learning (AIML). molecule bioproducts. This will address a
2. Cullis, PR and Hope, MJ 2017, Lipid Nanoparticle Systems
key challenge for industry partners seeking for Enabling Gene Therapies, Molecular Therapy, vol. 25,
Microfluidics-accelerated formulation to make plasmids at industrial scale. no. 7, pp. 1467-75, ISSN 1525-0016, https://doi.
org/10.1016/j.ymthe.2017.03.013.
Since first invented by Canon and Siemens Cancer formulations 3. Prazeres, DMF, Ferreira, GNM, Monteiro, GA, Cooney,
CL and Cabral, JMS 1999, Large-scale production of
for bubble-jet ink printing, microfluidics has pharmaceutical-grade plasmid DNA for gene therapy:
become a core component of continuous mRNA vaccines are an emerging platform problems and bottlenecks, Trends in Biotechnology, vol.
manufacturing. Microreactor technology for cancer immunotherapy4, and critically 17, no. 4, pp. 169-74, ISSN 0167-7799,
https://doi.org/10.1016/S0167-7799(98)01291-8.
enables rapid screening, and microfluidic needed as conventional monotherapeutic
4. Pardi, N, Hogan, M, Porter, F et al. 2018, mRNA vaccines
technology also make it possible to combine formulations are inadequate to fight — a new era in vaccinology, Nature Reviews Drug Discovery,
different process streams. This enables active stubborn cancers. New multimodal vol. 17, pp. 261–79, https://doi.org/10.1038/nrd.2017.243.
The University of Adelaide 2
THREE
Institute for Photonics and
Advanced Sensing (IPAS)
For enhanced process sensing
The core to control of advanced
DRIVING
biomanufacturing is the ability to estimate
bioprocess status using advanced sensing.
The University of Adelaide’s IPAS brings
together experimental physicists, chemists,
material scientists, biologists and medical
researchers to create and apply new sensing
FORCES
and measurement technologies, housed
in $96m headquarters. With additional
skills across advanced manufacturing and
rapid prototyping, IPAS is able to deliver
unique and highly competitive advantages to
industrial facilities and operations.
South Australian immunoGENomics
Cancer Institute (SAiGENCI)
Australian Institute for
For accelerated cancer research
Machine Learning (AIML)
SAiGENCI delivers translational
For the digital world research and clinical capability in cancer
Cooperatively funded by the South immunotherapy and cell therapy for all
Australian Government and the University Australians. The institute was established
of Adelaide ($2m pa), AIML methodologies by the University of Adelaide with the help
and expertise integrate artificial intelligence, of $80m in Commonwealth funding and
computer vision and deep learning into additional support from the Government of
medical and biomanufacturing processes. South Australia. Uniquely integrated with
AIML can oversee efficient predictive/pre- Adelaide Local Health Networks, it offers
emptive maintenance and provide demand pioneering training programs for clinicians
planning and supply chain optimisation. and the broader health and medical research
A boost by the Department of Education, workforce. SAiGENCI’s collaboration with
Skills and Employment has delivered a partners along Adelaide’s North Terrace
further $20m towards the new AIML Biomedical Precinct secures an essential
Centre for Augmented Reasoning—for translational pathway for industry-sponsored
research to improve human-computer and investigator-led clinical trials of mRNA
interactions and accelerate the products manufactured nearby at the
implementation of AIML discoveries. Thebarton Bioscience Precinct.
3
MULTIPLE
RESEARCH FUNDING
OPPORTUNITIES
The $20b Medical Research Future comprising vaccine, anti-viral and respiratory
Fund (MRFF) sovereign fund ensures medicine research. This will drive innovation,
long-term, sustainable funding contribute to global COVID-19 control
opportunities for research that will be efforts and develop facilities, infrastructure
enabled by a local biomanufacturing hub. and preparedness for inevitable
It is important to note the MRFF rapidly pandemics in the future.
responds to emerging threats to public International sources of research revenue
health, with >$650m pa disbursed for are extensive and diverse. The NIH
translational research activities. National Institute of Allergy and Infectious
In addition, the Australian Government Diseases has been provisionally budgeted
has committed $2.4b to a Coronavirus $6.25b for 2022 for research within the
(COVID-19) National Health Plan; the United States and throughout the world,
package provides support across primary with an additional $3.3b in emergency
care, aged care, hospitals and research, funds funnelled into clinical trials.
and includes $30m over two years for a
Coronavirus Research Response
The University of Adelaide 4OUR LEADERS
Adelaide. His research on solution and • Stability of Engineered Ferritin
protein chemistry has broadened our Nanovaccines Investigated by Combined
understanding of the mechanisms that Molecular Simulation and Experiments
determine the stability of therapeutic https://pubs.acs.org/doi/10.1021/acs.
macromolecules in liquid formulations jpcb.1c00276
and during biomanufacturing. Robert
• Virus-like particle preparation is improved
has experience in the biopharmaceutical,
by control over capsomere-DNA
medical diagnostic and medical device
interactions during chromatographic
industries, and was involved in the
purification https://onlinelibrary.wiley.
conversion of processes from the
Professor Chun-Xia Zhao laboratory-scale to the commercial-scale.
com/doi/10.1002/bit.27687
School of Chemical Engineering and Advanced Materials He has published more than 60 peer-
reviewed papers and has over 2,200 Google
Professor Chun-Xia Zhao is the newly Scholar citations, with an h-index 28.
appointed Professor of Bioengineering
and Nanotechnology at the University • Advances in liquid formulation of
of Adelaide. She is an ARC Future parenteral therapeutic proteins https://doi.
Fellow and member of the ARC College org/10.1016/j.biotechadv.2019.06.011
of Experts. Her research expertise spans • Control of globular protein thermal
microfluidics, nanomedicines, bio-inspired stability in aqueous formulations by the
nanotechnology and organs-on-a-chip. positively charged amino acid excipients
Chun-Xia’s research has attracted more https://doi.org/10.1016/j.xphs.2016.09.013
than $7m in research funding since 2011.
Professor Volker Hessel
This includes six ARC grants as the lead • Thermal stability of lysozyme as a function School of Chemical Engineering and Advanced Materials
or sole investigator; ARC Centre of of ion concentration: A reappraisal of
the relationship between the Hofmeister Professor Volker Hessel is Deputy
Excellence funding; and industry funding.
series and protein stability https://dx.doi. Dean (Research) at the University
Her focus is on innovative research and
org/10.1002%2Fpro.2355 of Adelaide. His research focus is on
translation. Professor Zhao has published
microfluidics, flow chemistry and plasma
more than 100 peer-reviewed articles
(catalytic) processing. He creates and
in leading journals (including Science
designs disruptive processes, guided by
Advances, Nature Communications) and 6
principles of sustainability and circularity
patents (with one licensed to
transition indicators. Volker’s research has
an international company).
applications in AgriFood (fertiliser, food
• Nanoparticle elasticity regulates waste-to-value), clean energy and in-space
phagocytosis and cancer cell uptake manufacturing (minerals, farming, food).
https://doi.org/10.1126/sciadv.aaz4316 He has research interests in the formulation
• Role of Nanoparticle Mechanical of new mRNA vaccines to enhance the
Properties in Cancer Drug Delivery medicinal product stability and for
https://doi.org/10.1021/acsnano.9b03924
Associate Professor Jingxiu Bi targeted delivery. Volker has published
School of Chemical Engineering and Advanced Materials more than 500 peer-reviewed publications
• Multiphase microfluidic synthesis of and has over 27,000 Google Scholar
micro- and nanostructures for Associate Professor Jingxiu Bi has citations, with an h-index 76.
pharmaceutical applications https://doi. more than 20 years’ research experience
org/10.1016/j.ces.2017.01.008 • Circular Economy Metrics for the Photo-
in biopharmaceutical molecular design
High-p,T Continuous Multistep Synthesis
and production process development.
of Vitamin D3 https://doi.org/10.1021/
She has made significant scientific
acssuschemeng.0c08330
contributions, leading a research team
focused on hepatitis B surface antigen • Ionic Liquid/Water Continuous-Flow
(HBsAg) vaccine bioprocess development System with Compartmentalized Spaces
and vaccine quality control, successfully for Automatic Product Purification of
scaling up the bioprocess to pilot scale to Biotransformation with Enzyme Recycling
produce HBsAg vaccine. Her research https://doi.org/10.1021/acs.iecr.0c02785
team focuses on vaccine molecular
design and stability, aided by molecular
simulation and bioprocess development.
Professor Robert Falconer Jingxiu has published more than 80 peer-
School of Chemical Engineering and Advanced Materials reviewed publications and 6 patents.
She has over 2,300 Google Scholar
Professor Robert Falconer is the newly citations with an h-index 28.
appointed Professor of Bioprocess
Engineering at the University of
5 The Adelaide Biomanufacturing Alliancewithin the biopharmaceutical industry,
process integration and advanced process
control using artificial intelligence. The
outcomes of Lukas’s research are of high
practical value for the production of future
vaccines, such as mRNA and viral
particles, as well as antibodies and
further therapeutic proteins.
• Continuous downstream bioprocessing
Professor Ian Reid Professor Javen Qinfeng Shi for intensified manufacture of
biopharmaceuticals and antibodies https://
School of Computer Science School of Computer Science
Australian Institute for Machine Learning (AIML) Australian Institute for Machine Learning (AIML) doi.org/10.1016/j.ces.2020.116272
• Comparative evaluation of integrated
Professor Ian Reid is Head of the Professor Javen Qinfeng Shi is the purification pathways for bacterial modular
School of Computer Science and the Founding Director of the Probabilistic polyomavirus major capsid protein VP1
senior researcher at the Australian Graphical Model Group and Director in to produce virus-like particles using high
Institute for Machine Learning, University Advanced Releasing and Learning of the throughput process technologies https://
of Adelaide. He is a 2021 Fellow of the Australian Institute for Machine Learning doi.org/10.1016/j.chroma.2021.461924
Academy of Technological Sciences and (AIML) at the University of Adelaide.
Engineering (ATSE), Deputy Director of He is an international leader in the • Virus-like particle preparation is improved
the ARC Centre of Excellence in Robotic development of artificial intelligence by control over capsomeres-DNA
Vision, and a former ARC Australian and machine learning, and has transferred interactions during chromatographic
Laureate Fellow. His research interests his research to diverse industries. purification https://doi.org/10.1002/
include robotic and active vision, visual These include agriculture, mining, sport, bit.27687
tracking, SLAM, human motion capture bushfire management, water utility,
and intelligent visual surveillance, with an health, education, and biomanufacturing
emphasis on real-time implementations (including mRNA vaccine manufacturing).
whenever possible. Ian has published more Qinfeng has published more than 80 peer-
than 200 peer-reviewed publications and reviewed publications and has over
has over 35,000 Google Scholar 5,500 Google Scholar citations,
citations, with an h-index 87. with an h-index 31.
• Variational Bayesian Dropout with a
Hierarchical Prior https://openaccess.
thecvf.com/content_CVPR_2019/papers/
Liu_Variational_Bayesian_Dropout_ Professor Maziar Arjomandi
With_a_Hierarchical_Prior_CVPR_ School of Mechanical Engineering
2019_paper.pdf
Professor Maziar Arjomandi is the
• Counterfactual Vision-and-Language
Research Director of the School of
Navigation: Unravelling the Unseen https://
Mechanical Engineering at the University
papers.nips.cc/paper/2020/hash/39016cfe07
of Adelaide. He is an international expert
9db1bfb359ca72fcba3fd8-Abstract.html
Professor Simon Lucey in fluid mechanics, having made original
• Counterfactual Vision and Language contributions in several research fields,
School of Computer Science
Learning https://openaccess.thecvf.com/ including wall-bounded flows, heat transfer,
Australian Institute for Machine Learning (AIML)
content_CVPR_2020/papers/Abbasnejad_ multiphase and complex flows, micro-
Professor Simon Lucey is Director Counterfactual_Vision_and_Language_ fluids and biological flows. He has research
of the Australian Institute for Machine Learning_CVPR_2020_paper.pdf interests in the microfluidic modelling of
Learning at the University of Adelaide mRNA vaccines. Maziar has published
and a former ARC Future Fellow. more than 246 peer-reviewed publications
His research interests are in computer and 4 patents and has over 3,800 Google
vision and machine learning, with specific Scholar citations, with an h-index 32.
interests in their application to human • Acoustically-driven drug delivery to
behaviour. He has secured over $35m in maxillary sinuses: Aero-acoustic analysis
pure and commercial research funding, https://doi.org/10.1016/j.ejps.2020.105398
including from the ARC and the US
National Science Foundation (NSF). • Transitional turbulent flow in a stenosed
Simon has published more than 100 coronary artery with a physiological
peer-reviewed publications and has pulsatile flow https://doi.org/10.1002/
Lukas Gerstweiler cnm.3347
over 11,000 Google Scholar citations,
School of Chemical Engineering and Advanced Materials
with an h-index 52. • Effect of artery curvature on the coronary
Mr Luke Gerstweiler is a final-year PhD fractional flow reserve https://doi.
student in chemical engineering at the org/10.1063/5.0042601
University of Adelaide. His research focuses
on advanced and intensified production
technologies for future vaccine candidates.
In particular, he focuses on the translation
from batch to continuous production
The University of Adelaide 6KAURNA ACKNOWLEDGEMENT
We acknowledge and pay our respects to the Kaurna
people, the original custodians of the Adelaide Plains
and the land on which the University of Adelaide’s
campuses at North Terrace, Waite, and Roseworthy
are built. We acknowledge the deep feelings of
attachment and relationship of the Kaurna people
to country and we respect and value their past,
present and ongoing connection to the land and
cultural beliefs. The University continues to develop
respectful and reciprocal relationships with all
Indigenous peoples in Australia, and with other
Indigenous peoples throughout the world.
FOR FURTHER ENQUIRIES
The University of Adelaide SA 5005 Australia
ENQUIRIES enquiries.dvcr@adelaide.edu.au
TELEPHONE +61 8 8313 3278
FREE-CALL 1800 061 459
www.adelaide.edu.au/research
facebook.com/uniofadelaide
twitter.com/uniofadelaide
UniversityOfAdelaide
weibo.com/uniadelaide
© The University of Adelaide.
Published June 2021 6423-029
CRICOS 00123M
DISCLAIMER The information in this publication is
current as at the date of printing and is subject to
change. You can find updated information on our
website at adelaide.edu.au or contact us on 1800 061 459.
The University of Adelaide assumes no responsibility for
the accuracy of information provided by third parties.You can also read
